What is the rationale for using continuous renal replacement therapy (CRRT) in acute liver failure (ALF)?

CRRT in Acute Liver Failure: Rationale and Evidence

CRRT should be initiated early in ALF patients to control hyperammonemia and improve survival, particularly when ammonia levels exceed 150 μmol/L, as this represents an emerging standard of care that can enhance both overall survival and transplant-free survival. 1, 2

Primary Rationale for CRRT in ALF

The fundamental basis for using CRRT in ALF centers on hyperammonemia management, which is directly linked to cerebral edema and intracranial hypertension—major causes of mortality in this population 3. Unlike patients with chronic liver failure who develop adaptive mechanisms, ALF patients lack preconditioning to cope with elevated ammonia levels and are therefore more vulnerable to life-threatening neurological complications 3.

Key Pathophysiologic Considerations

• Ammonia as an independent risk factor: Ammonia levels >200 μmol/L are associated with intracranial hypertension in 55% of ALF patients 3
• Cerebral edema development: Hyperammonemia directly contributes to increased intracranial pressure, which is associated with increased mortality 4
• Multiorgan failure: ALF patients frequently develop acute kidney injury (30-50% of cases), requiring renal support beyond ammonia clearance 5

Evidence Supporting CRRT Use

Survival Benefits

The most compelling recent evidence comes from a 2024 systematic review and meta-analysis demonstrating:

• Improved overall survival (RR 0.83,95% CI 0.70-0.99, p=0.04) 2
• Enhanced transplant-free survival (RR 0.65,95% CI 0.49-0.85, p=0.002) 2
• Bridge to transplantation: CRRT provides hemodynamic stability while awaiting liver transplantation 6

Ammonia Reduction as Prognostic Marker

The 48-hour ammonia reduction is critical: For every 10% decrease in ammonia from baseline at 48 hours, the likelihood of survival increases by 50% 6. Inability to reduce ammonia by 48 hours confers poor prognosis 6. This provides a concrete therapeutic target and prognostic indicator.

Clinical Implementation Algorithm

When to Initiate CRRT

1. Ammonia threshold: Consider when ammonia >150 μmol/L 3
2. Earlier is better: Time to initiate CRRT from ICU admission was lower in survivors versus non-survivors 6
3. Don't wait for traditional dialysis indications: The indication extends beyond conventional renal criteria 5

CRRT Prescription Specifics

• Modality preference: Continuous renal replacement therapy is preferred over intermittent hemodialysis due to hemodynamic instability common in ALF 7, 8
• Anticoagulation: Regional anticoagulation (citrate) is preferred over systemic anticoagulation given bleeding tendency in liver failure 7
• High-dose therapy: Early and high-dose CRRT showed maximum survival benefit in the first 14 days 6

Important Caveats and Pitfalls

What CRRT Does NOT Replace

The 2017 AGA guidelines notably recommend against extracorporeal artificial liver support systems outside clinical trials 4. This is distinct from CRRT for renal support and ammonia clearance. Seven RCTs involving 415 ALF patients showed no improvement in survival with artificial liver support systems, though more recent trials (past 20 years) showed marginal benefit 4.

Plasma Exchange Consideration

For the sickest ALF patients with hyperammonemia, plasma exchange may have a role 1. The 2023 Critical Care Medicine guidelines suggest using plasma exchange when available for critically ill ALF patients with hyperammonemia (conditional recommendation, low quality evidence) 3. This represents an adjunctive therapy, not a replacement for CRRT.

Monitoring Considerations

• Avoid routine invasive ICP monitoring: The 2023 guidelines suggest against invasive ICP monitoring for ALF patients with advanced-grade encephalopathy (conditional recommendation, very low quality evidence) 3
• Track ammonia levels serially: Use 48-hour ammonia reduction as a therapeutic endpoint 6
• Assess for AKI: CRRT addresses both hyperammonemia and renal dysfunction simultaneously 5

Divergent Evidence and Nuances

While the AGA 2017 guidelines 4 do not specifically address CRRT (they focus on artificial liver support systems), the more recent 2023 Critical Care Medicine guidelines 3 and 2024-2025 research 1, 2 represent an evolution in understanding. The evidence base has shifted toward recognizing CRRT as standard care for hyperammonemia control, distinct from the unproven artificial liver support systems.

The pediatric literature 6 provides particularly strong mechanistic evidence for the ammonia-reduction hypothesis, showing clear dose-response relationships that likely apply to adults.

Practical Approach

For any ALF patient in the ICU:

1. Check ammonia level on admission and serially
2. If ammonia >150 μmol/L, initiate CRRT promptly (don't wait for traditional dialysis indications)
3. Use continuous modality with regional anticoagulation
4. Target >10% ammonia reduction every 48 hours
5. Consider plasma exchange for refractory hyperammonemia
6. Transfer to transplant center early for definitive management

This approach maximizes the window for spontaneous recovery or successful bridge to transplantation 1, 2, 6.